Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- FHCC Overlake — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Highline Medical Center-Main Campus — Burien, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- Overlake Medical Center — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
- Madigan Army Medical Center — Tacoma, Washington
Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Sites in Washington: - Swedish Cancer Institute - Edmonds /ID# 266356 — Edmonds, Washington
- Swedish Cancer Institute - Issaquah /ID# 266358 — Issaquah, Washington
- Vista Oncology - East Olympia /ID# 261360 — Olympia, Washington
- Virginia Mason Hospital & Medical Center /ID# 260549 — Seattle, Washington
- Swedish Medical Center - Seattle /ID# 260370 — Seattle, Washington
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Washington: - Research Site — Tacoma, Washington
Phase 3 Recruiting Industry
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had be…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
- Summit Cancer Centers — Spokane, Washington
- Northwest Medical Specialties — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Washington: - University of Washington — Seattle, Washington
Phase 3 Recruiting Industry
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…
Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Washington: - University of Washington Fred Hutch Cancer Center — Seattle, Washington
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Washington: - Northwest Medical Specialties — Tacoma, Washington
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Washington: - Overlake Medical Center — Bellevue, Washington
- Valley Medical Center — Renton, Washington
- Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Washington: - Overlake Medical Center — Bellevue, Washington
- Valley Medical Center — Renton, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital — Yakima, Washington
Phase 2 Recruiting NIH
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Washington: - Northwest Cancer Specialists (Compass Oncology) ( Site 8000) — Vancouver, Washington
Phase 2 Recruiting Industry
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…
Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Fred Hutchinson Cancer — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymph…
Sponsor: Dren Bio
NCT ID: NCT05475925
Sites in Washington: - Dren Investigational Site — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05421663
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
Phase 2 Recruiting Network
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who …
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT06859424
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…
Sponsor: Debiopharm International SA
NCT ID: NCT05765812
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 2 Recruiting Academic/Other
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-el…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT04626791
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington